Acute renal failure in patients with malnutrition following mitral valve replacement

1984 ◽  
Vol 14 (1) ◽  
pp. 6-14 ◽  
Author(s):  
Shigeki Morita ◽  
Jiro Tanaka ◽  
Kouichi Tokunaga
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement

scholarly journals Mitral Valve Replacement Using Subvalvular Apparatus: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 23 (3) ◽  
pp. E385-E392
Author(s):  
Wan Chin Hsieh ◽  
Anas Aboud ◽  
Brandon Michael Henry ◽  
Chung Dann Kan ◽  
Mohamed Omara ◽  
...  
Keyword(s):  
Renal Failure ◽  
Mitral Valve ◽  
Length Of Stay ◽  
Clinical Outcomes ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Meta Analysis ◽  
Significant Difference ◽  
Long Term Mortality

Background: To assess clinical outcomes among participants undergoing mitral valve replacement with preservation of subvalvular apparatus. Methods: Electronic databases, including PubMed, Embase, Science Direct, World of Science, Scopus, Biosis, SciElo and Cochrane library, were probed using an extensive search strategy. Studies that reported at least one clinical outcome, such as morbidity, mortality, early 30-day mortality, myocardial failure, survival, late cerebrovascular events, length of stay, or major operative complications (stroke, prolonged ventilation, and reoperation for bleeding, renal failure, and sternal infection) were considered for inclusion. Data was extracted and pooled into a meta-analysis in RevMan (version 5.3) using a random-effects model. Results: A total of 21 studies with 5,106 participants (age range: 27.3-69.2 years) were included in this meta-analysis. Preservation of the subvalvular apparatus during MVR significantly reduces the risk of long-term mortality (OR: 0.46; 95% CI: 0.33-0.64), but not early mortality (OR: 0.76; 95% CI: 0.12-4.93). No significant difference ejection fraction was observed (SMD: 0.10; 95% CI: -0.44-0.64). Similarly, there was no significant difference in the risk of stroke, renal failure, and pneumonia between C-MVR and in the control group. Conclusion: MVR with the preservation of subvalvular apparatus improves clinical outcomes, such as long-term mortality, hospital length of stay, pneumonia, and bleeding. There is no significant difference in the risk of stroke, renal failure, or ICU length of stay. However, there is very limited data available with respect to bleeding, sepsis, and nosocomial infections.

Secondary mitral valve replacement in antiphospholipid syndrome and chronic renal failure

2001 ◽  
Vol 49 (12) ◽  
pp. 728-731 ◽  
Author(s):  
Yasuyuki Kato ◽  
Fumitaka Isobe ◽  
Yasuyki Sasaki ◽  
Hiroshi Kumano ◽  
Keima Nagamachi ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Antiphospholipid Syndrome

Choice of prosthesis in mitral valve replacement and concomitant coronary revascularization

2006 ◽  
Vol 54 (S 1) ◽  
Author(s):  
T Günther ◽  
N Augustin ◽  
R Bauernschmitt ◽  
C Nöbauer ◽  
M Wottke ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Coronary Revascularization

Postoperative Nesiritide Use following High-Risk Mitral Valve Replacement

2004 ◽  
Vol 7 (3) ◽  
pp. E189-E190 ◽  
Author(s):  
John W. C. Entwistle, III ◽  
David E. McLoughlin ◽  
Kourosh Baghelai
Keyword(s):  
High Risk ◽  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement

Next generation russian biological prosthesis “UniLin” for mitral valve replacement: first experience

2017 ◽  
Vol 59 (2) ◽  
pp. 98-104
Author(s):  
A.M. Karas'kov ◽  
S.I. Zheleznev ◽  
N.V. Rogulina ◽  
A.V. Sapegin ◽  
Yu.N. Odarenko ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Next Generation ◽  
Biological Prosthesis
Sign in / Sign up

Export Citation Format

Share Document